Oscar McGuinness

Co-founder & Head of Private Markets

LSE BSc Finance

Articles 19

  1. Private Markets

    Why Veritas Could Pay 940p for Bodycote

    The London discount looked like the reason UK companies keep being bought. It was really the lender's underwriting policy, and that sets the ceiling regardless of where the shares trade.

  2. Markets

    The New Rules of Pharma M&A

    Big Pharma is acquiring earlier and accepting greater scientific risk for unproven drugs. The driver is not confidence in the science but the fear of a rival securing the next blockbuster first, as a $300bn patent cliff bears down on the industry.

  3. Markets

    AstraZeneca's Bet on the Future of COPD Treatment

    A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation.

  4. Private Markets

    Why EQT Had to Bid Four Times for Intertek

    EQT needed four bids to take Intertek private, and the sequence reveals less about price than about who now sets the value of a FTSE 100 company, and why London keeps losing profitable firms to private buyers.

  5. Markets

    Inside Vertex's $10 Billion Bet on Crinetics

    Vertex's $10 billion acquisition of Crinetics is about far more than adding another drug to its portfolio. It is a strategic bet on an endocrinology platform that could fuel the company's next phase of growth.

  6. Markets

    Who Should Profit from Britain's Autism Crisis?

    As NHS waiting lists for autism assessments pass 200,000, private capital is flowing into neurodiversity services – forcing the question of whether profit and patient care can ever be aligned.

  7. Markets

    Has the FDA Just Revived Gene Therapy?

    A single FDA reversal sent Regenxbio's shares soaring and reignited optimism across gene therapy - but one favourable decision cannot solve the commercial challenges that pushed the industry into crisis.

  8. Markets

    The $100 Billion Weight-Loss Question Nobody Can Answer

    Novo Nordisk and Eli Lilly have proven GLP-1 drugs can deliver surgery-level weight loss - but with patients regaining much of it after stopping, the market's real value may depend on long-term adherence rather than who wins on efficacy.

  9. Markets

    The Wall Street Bet on a $5,900 Ticket

    A Connecticut credit firm is lending millions against World Cup resale tickets, betting the markup holds. The trade exposes a wider story about how Wall Street is learning to finance scarcity.

  10. Private Markets

    Week in Review: Private Capital & Dealmaking

    From Blackstone's bid for Senior plc to the largest LBO in history and a regulatory clash threatening the private credit ratings ecosystem, this week laid bare the tensions running through global private capital markets.

  11. Markets

    The $3.8 Trillion Logjam

    Record unsold assets, zombie funds, and pension pain. Why the private equity industry is at a structural turning point.

  12. Markets

    Wall Street's Blind Spot

    Retail investors are pulling billions, insiders say defaults are already here, and banks are quietly tightening credit. The mixed signals across private credit mask a single uncomfortable truth.

  13. Markets

    Defaults Could Double, Warns Partners Group

    Partners Group Chair Steffen Meister warns AI will create an asymmetric disaster for private credit, where lenders absorb the losses from disrupted companies while capturing none of the upside.

  14. Markets

    Blackstone Hit By Record Redemptions

    Investors pulled $3.7 billion from the world's largest private credit fund. BCRED has posted its first ever net outflows, signalling a turning point for the entire industry.

  15. Markets

    Blue Owl Locks Out Investors

    Blue Owl permanently restricts investors from withdrawing cash from its inaugural retail debt fund, backtracking on plans to reopen redemptions this quarter.